Enterprise Value

-25.56M

Cash

56.55M

Avg Qtr Burn

-10.94M

Short % of Float

0.62%

Insider Ownership

0.70%

Institutional Own.

43.33%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ME-344 (Mitochondrial Inhibitor) + bevacizumab Details
Cancer, Solid tumor/s, Colorectal cancer

Phase 1b

Update

Voruciclib (CDK Inhibitor) +/- venetoclax Details
B-cell malignancies, Acute myeloid leukemia, Cancer

Phase 1

Data readout

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued